当前位置: 首页 >> 检索结果
1241. NTPDase8 protects mice from intestinal inflammation by limiting P2Y6 receptor activation: identification of a new pathway of inflammation for the potential treatment of IBD.
作者: Mabrouka Salem.;Joanna Lecka.;Julie Pelletier.;Danielle Gomes Marconato.;Aline Dumas.;Luc Vallières.;Gaetan Brochu.;Bernard Robaye.;Christian Jobin.;Jean Sévigny.
来源: Gut. 2022年71卷1期43-54页
Nucleotides are danger signals that activate inflammatory responses via binding P2 receptors. The nucleoside triphosphate diphosphohydrolase-8 (NTPDase8) is an ectonucleotidase that hydrolyses P2 receptor ligands. We investigated the role of NTPDase8 in intestinal inflammation.
1242. Possible tumour cell reimplantation during curative endoscopic therapy of superficial Barrett's carcinoma.
作者: Hanno Ehlken.;Rüdiger Schmitz.;Sabine Riethdorf.;Lutz Riethdorf.;Jenny Krause.;Karl-Frederick Karstens.;Jörg Schrader.;Fabrice Viol.;Anastasios Giannou.;William Sterlacci.;Michael Vieth.;Till Clauditz.;Christian Kähler.;Oliver Mann.;Jakob R Izbicki.;Samuel Huber.;Klaus Pantel.;Thomas Rösch.
来源: Gut. 2022年71卷2期277-286页
Endoscopic resection has been established as curative therapy for superficial cancer arising from Barrett's oesophagus (BE); recurrences are very rare. Based on a case series with unusual and massive early recurrences, we analyse the issue of tumour cell reimplantation.
1243. PI3K-driven HER2 expression is a potential therapeutic target in colorectal cancer stem cells.
作者: Laura Rosa Mangiapane.;Annalisa Nicotra.;Alice Turdo.;Miriam Gaggianesi.;Paola Bianca.;Simone Di Franco.;Davide Stefano Sardina.;Veronica Veschi.;Michele Signore.;Sven Beyes.;Luca Fagnocchi.;Micol Eleonora Fiori.;Maria Rita Bongiorno.;Melania Lo Iacono.;Irene Pillitteri.;Gloria Ganduscio.;Gaspare Gulotta.;Jan Paul Medema.;Alessio Zippo.;Matilde Todaro.;Ruggero De Maria.;Giorgio Stassi.
来源: Gut. 2022年71卷1期119-128页
Cancer stem cells are responsible for tumour spreading and relapse. Human epidermal growth factor receptor 2 (HER2) expression is a negative prognostic factor in colorectal cancer (CRC) and a potential target in tumours carrying the gene amplification. Our aim was to define the expression of HER2 in colorectal cancer stem cells (CR-CSCs) and its possible role as therapeutic target in CRC resistant to anti- epidermal growth factor receptor (EGFR) therapy.
1244. Global burden of disease: acute-on-chronic liver failure, a systematic review and meta-analysis.
作者: Gabriel Mezzano.;Adria Juanola.;Andres Cardenas.;Esteban Mezey.;James P Hamilton.;Elisa Pose.;Isabel Graupera.;Pere Ginès.;Elsa Solà.;Ruben Hernaez.
来源: Gut. 2022年71卷1期148-155页
Acute-on-chronic liver failure (ACLF) is characterised by acute decompensation of cirrhosis associated with organ failures. We systematically evaluated the geographical variations of ACLF across the world in terms of prevalence, mortality, aetiology of chronic liver disease (CLD), triggers and organ failures.
1245. Placental growth factor promotes tumour desmoplasia and treatment resistance in intrahepatic cholangiocarcinoma.
作者: Shuichi Aoki.;Koetsu Inoue.;Sebastian Klein.;Stefan Halvorsen.;Jiang Chen.;Aya Matsui.;Mohammad R Nikmaneshi.;Shuji Kitahara.;Tai Hato.;Xianfeng Chen.;Kazumichi Kawakubo.;Hadi T Nia.;Ivy Chen.;Daniel H Schanne.;Emilie Mamessier.;Kohei Shigeta.;Hiroto Kikuchi.;Rakesh R Ramjiawan.;Tyge Ce Schmidt.;Masaaki Iwasaki.;Thomas Yau.;Theodore S Hong.;Alexander Quaas.;Patrick S Plum.;Simona Dima.;Irinel Popescu.;Nabeel Bardeesy.;Lance L Munn.;Mitesh J Borad.;Slim Sassi.;Rakesh K Jain.;Andrew X Zhu.;Dan G Duda.
来源: Gut. 2022年71卷1期185-193页
Intrahepatic cholangiocarcinoma (ICC)-a rare liver malignancy with limited therapeutic options-is characterised by aggressive progression, desmoplasia and vascular abnormalities. The aim of this study was to determine the role of placental growth factor (PlGF) in ICC progression.
1246. PBMC transcriptomics identifies immune-metabolism disorder during the development of HBV-ACLF.
作者: Jiang Li.;Xi Liang.;Jing Jiang.;Lingling Yang.;Jiaojiao Xin.;Dongyan Shi.;Yingyan Lu.;Jun Li.;Keke Ren.;Hozeifa Mohamed Hassan.;Jianing Zhang.;Pengcheng Chen.;Heng Yao.;Jiaqi Li.;Tianzhou Wu.;Linfeng Jin.;Ping Ye.;Tan Li.;Huafen Zhang.;Suwan Sun.;Beibei Guo.;Xingping Zhou.;Qun Cai.;Jiaxian Chen.;Xiaowei Xu.;Jianrong Huang.;Shaorui Hao.;Jinqiu He.;Shaojie Xin.;Di Wang.;Jonel Trebicka.;Xin Chen.;Jun Li.; .
来源: Gut. 2022年71卷1期163-175页
Hepatitis B virus-related acute-on-chronic liver failure (HBV-ACLF) pathophysiology remains unclear. This study aims to characterise the molecular basis of HBV-ACLF using transcriptomics.
1247. Sofosbuvir/velpatasvir with or without low-dose ribavirin for patients with chronic hepatitis C virus infection and severe renal impairment.
作者: Chen-Hua Liu.;Chi-Yi Chen.;Wei-Wen Su.;Kuo-Chih Tseng.;Ching-Chu Lo.;Chun-Jen Liu.;Jyh-Jou Chen.;Cheng-Yuan Peng.;Yu-Lueng Shih.;Sheng-Shun Yang.;Chia-Sheng Huang.;Ke-Jhang Huang.;Chi-Yang Chang.;Ming-Chang Tsai.;Wei-Yu Kao.;Yo-Jen Fang.;Po-Yueh Chen.;Pei-Yuan Su.;Chih-Wei Tseng.;Jow-Jyh Huang.;Pei-Lun Lee.;Hsueh-Chou Lai.;Tsai-Yuan Hsieh.;Chung-Hsin Chang.;Yi-Jie Huang.;Fu-Jen Lee.;Chun-Chao Chang.;Jia-Horng Kao.
来源: Gut. 2022年71卷1期176-184页
Data regarding the real-world effectiveness and safety of sofosbuvir/velpatasvir (SOF/VEL) with or without low-dose ribavirin (RBV) in patients with chronic hepatitis C virus (HCV) infection and severe renal impairment (RI) are limited. We evaluated the performance of SOF/VEL with or without low-dose RBV in HCV-infected patients with chronic kidney disease stage 4 or 5.
1248. First-line treatment with infliximab versus conventional treatment in children with newly diagnosed moderate-to-severe Crohn's disease: an open-label multicentre randomised controlled trial.
作者: Maria M E Jongsma.;Martine A Aardoom.;Martinus A Cozijnsen.;Merel van Pieterson.;Tim de Meij.;Michael Groeneweg.;Obbe F Norbruis.;Victorien M Wolters.;Herbert M van Wering.;Iva Hojsak.;Kaija-Leena Kolho.;Thalia Hummel.;Janneke Stapelbroek.;Cathelijne van der Feen.;Patrick F van Rheenen.;Michiel P van Wijk.;Sarah T A Teklenburg-Roord.;Marco W J Schreurs.;Dimitris Rizopoulos.;Michail Doukas.;Johanna C Escher.;Janneke N Samsom.;Lissy de Ridder.
来源: Gut. 2022年71卷1期34-42页
In newly diagnosed paediatric patients with moderate-to-severe Crohn's disease (CD), infliximab (IFX) is initiated once exclusive enteral nutrition (EEN), corticosteroid and immunomodulator therapies have failed. We aimed to investigate whether starting first-line IFX (FL-IFX) is more effective to achieve and maintain remission than conventional treatment.
1249. Non-alcoholic fatty liver disease and risk of incident chronic kidney disease: an updated meta-analysis.
作者: Alessandro Mantovani.;Graziana Petracca.;Giorgia Beatrice.;Alessandro Csermely.;Amedeo Lonardo.;Jörn M Schattenberg.;Herbert Tilg.;Christopher D Byrne.;Giovanni Targher.
来源: Gut. 2022年71卷1期156-162页
Studies reported a significant association between non-alcoholic fatty liver disease (NAFLD) and increased risk of chronic kidney disease (CKD). However, whether this risk changes with increasing severity of NAFLD remains uncertain. We performed a meta-analysis of observational studies to quantify the magnitude of the association between NAFLD and risk of incident CKD.
|